Outcomes
bleeding, death, TOAST, Stroke, hemorrhagic, dementia, physical disability, ischemic stroke
BLEEDING, STROKE, ACUTE STROKE, PHYSICAL DISABILITY, ISCHEMIC STROKE, INTRACRANIAL HEMORRHAGE, SECONDARY, EVENTS
The primary outcome of ASPREE was disability-free survival (defined as survival free of physical disability and dementia), and this was not different between aspirin and placebo groups. This has been reported, along with overall mortality and cardiovascular outcomes.Stroke and hemorrhagic events were predetermined secondary end points. Suspected events within these categories were independently adjudicated by at least 2 members of an expert committee (G.C.C., J.D.W., C.B.E., and G.A.D.). Adjudications were supported by copies of patient routine hospital care records; these included results of key investigations, such as reports from brain and vascular imaging studies and cardiological testing. Disagreements were adjudicated by a third member and consensus reached. Further details of the adjudication processes were described previously.Using modified Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria, 4 subgroups of ischemic stroke were reported.Intracranial hemorrhage was reported according to the location identified on imaging (ie, basal ganglionic, lobar, brainstem, or other) or as subarachnoid, subdural, or extradural. Such bleeding was required to have led to hospitalization, prolonged hospitalization, surgery, or death.